Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline.
Tung N, Ricker C, Messersmith H, Balmaña J, Domchek S, Stoffel EM, Almhanna K, Arun B, Chavarri-Guerra Y, Cohen SA, Cragun D, Crew KD, Hall MJ, Idos G, Lopez G, Pal T, Pirzadeh-Miller S, Pritchard C, Rana HQ, Swami U, Vidal GA. Tung N, et al. Among authors: vidal ga. J Clin Oncol. 2024 Jul 20;42(21):2599-2615. doi: 10.1200/JCO.24.00662. Epub 2024 May 17. J Clin Oncol. 2024. PMID: 38759122
Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy.
Heath E, Dyson G, Ribeiro JR, Xiu J, Poorman K, Mamdani H, Al-Hallak MN, Shields AF, Elayoubi JA, Winer IS, Cackowski FC, Puckrein GA, Lopes GL, Jones N, Hauke RJ, Kareff SA, Radovich M, Sledge GW, Spetzler DB, Vidal GA, Marshall JL. Heath E, et al. Among authors: vidal ga. Cancer Res Commun. 2024 Oct 1;4(10):2598-2609. doi: 10.1158/2767-9764.CRC-24-0321. Cancer Res Commun. 2024. PMID: 39172022 Free PMC article.
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.
Goetz MP, Bagegni NA, Batist G, Brufsky A, Cristofanilli MA, Damodaran S, Daniel BR, Fleming GF, Gradishar WJ, Graff SL, Grosse Perdekamp MT, Hamilton E, Lavasani S, Moreno-Aspitia A, O'Connor T, Pluard TJ, Rugo HS, Sammons SL, Schwartzberg LS, Stover DG, Vidal GA, Wang G, Warner E, Yerushalmi R, Plourde PV, Portman DJ, Gal-Yam EN. Goetz MP, et al. Among authors: vidal ga. Ann Oncol. 2023 Dec;34(12):1141-1151. doi: 10.1016/j.annonc.2023.09.3104. Ann Oncol. 2023. PMID: 38072514 Free article. Clinical Trial.
Molecular characterization of ESR1 variants in breast cancer.
Heeke AL, Elliott A, Feldman R, O'Connor HF, Pohlmann PR, Lynce F, Swain SM, Nunes MR, Magee D, Oberley MJ, Swenson J, Vidal G, Isaacs C, Schwartzberg L, Korn WM, Tan AR. Heeke AL, et al. Breast Cancer Res Treat. 2022 Nov;196(2):279-289. doi: 10.1007/s10549-022-06740-y. Epub 2022 Sep 20. Breast Cancer Res Treat. 2022. PMID: 36125660
Racial and Ethnic Inequities at the Practice and Physician Levels in Timely Next-Generation Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer Treated in the US Community Setting.
Vidal GA, Jain N, Fisher A, Sheinson D, Lofgren KT, Ma E, Yu E, Comment L, Miksad R, Sincan M, Martin RL, Zuniga R, Daniel D. Vidal GA, et al. JCO Oncol Pract. 2024 Mar;20(3):370-377. doi: 10.1200/OP.23.00253. Epub 2024 Jan 9. JCO Oncol Pract. 2024. PMID: 38194619
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results.
Schmid P, Turner NC, Barrios CH, Isakoff SJ, Kim SB, Sablin MP, Saji S, Savas P, Vidal GA, Oliveira M, O'Shaughnessy J, Italiano A, Espinosa E, Boni V, White S, Rojas B, Freitas-Junior R, Chae Y, Bondarenko I, Lee J, Torres Mattos C, Martinez Rodriguez JL, Lam LH, Jones S, Reilly SJ, Huang X, Shah K, Dent R. Schmid P, et al. Among authors: vidal ga. Clin Cancer Res. 2024 Feb 16;30(4):767-778. doi: 10.1158/1078-0432.CCR-23-2084. Clin Cancer Res. 2024. PMID: 38060199 Free PMC article. Clinical Trial.
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, Färkkilä A, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P. Konstantinopoulos PA, et al. Among authors: vidal ga. JAMA Oncol. 2019 Aug 1;5(8):1141-1149. doi: 10.1001/jamaoncol.2019.1048. JAMA Oncol. 2019. PMID: 31194228 Free PMC article.
Advancing Inclusive Research (AIR) Site Alliance: Facilitating the inclusion of historically underrepresented people in oncology and ophthalmology clinical research.
Vidal GA, Chalela P, Curry AN, El-Rayes B, Halmos B, Herrera AF, Kapoor KG, Kaur S, Mahadevan D, Mesa R, Ramirez A, Sleckman B, Wagner AL, Bhagat R, Brown I, Cruz L, Funwie A, Highsmith Q, Richie N, McKenzie M. Vidal GA, et al. Contemp Clin Trials. 2024 Feb;137:107416. doi: 10.1016/j.cct.2023.107416. Epub 2023 Dec 16. Contemp Clin Trials. 2024. PMID: 38109966 Free article.
55 results